Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06655064 · ClinicalTrials.gov registry record
Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations
A clinical trial, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- Terminated
- Registry status
- 120
- Enrollment target
NCT06655064: Clinical Trial study, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
NCT06655064 is a clinical trial that was terminated before completion, run by Telix Pharmaceuticals (Innovations) Pty Limited. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06655064 was terminated before completion, sponsored by Telix Pharmaceuticals (Innovations) Pty Limited.
- TERMINATED
- Registry status
- 120 participants
- Enrollment target
Study Summary
The purpose of this observational research registry is to understand the real-world use of Illuccix PET/CT in prostate cancer, and how results from this testing impact patient's treatment and prostate cancer journey over time. It will follow subjects and the diagnostic testing and therapy they receive for their prostate cancer. Subjects will not be administered any medical diagnostic testing or therapy that they would not have normally undergone outside of participation in the registry.
Primary Outcome
Long term outcomes of patients with newly diagnosed or recurrent disease prostate cancer or those being evaluated for radioligand therapy, who undergo 68Ga-PSMA-11PET/CT imaging for clinical management.
Interventions
- OTHER None- Observational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-01-30 |
| Est. Completion | 2025-06-17 |
Why NCT06655064 stopped before completion
NCT06655064 is an observational study that tracks outcomes without assigning an intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which None- Observational is the first listed.
NCT06655064 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06655064 about?
NCT06655064 is a clinical study titled "Registry to Evaluate Long-Term Outcomes in Patients Who Undergo 68-Ga-PSMA-11 PET/CT Imaging Evaluations". The purpose of this observational research registry is to understand the real-world use of Illuccix PET/CT in prostate cancer, and how results from this testing impact patient's treatment and prostate cancer journey over time. It will follow subjects and the diagnostic testing and therapy they recei...
What is the current status of trial NCT06655064?
This trial is currently terminated. The enrollment target is 120 participants. The study started on 2025-01-30. Estimated completion is 2025-06-17.
What interventions are being tested in trial NCT06655064?
The interventions under investigation include: None- Observational (OTHER).
Who is sponsoring clinical trial NCT06655064?
This trial is sponsored by Telix Pharmaceuticals (Innovations) Pty Limited, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI